Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Ibrutinib in Recurrent/Refractory PCNSL
NCT03581942Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2018
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of copanlisib and ibrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2018; status: completed.
02
Drugs
copanlisibibrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT03581942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03581942.